Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. However, the serum concentration-toxicity relationship has not yet been determined. The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
110
ofloxacin treatment in patients with bone and joint infections
questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
CHU Amiens
Amiens, France
RECRUITINGFrequency of one adverse reaction attributable to ofloxacin in patients with bone and joint infections
Frequency of at least one adverse reaction attributable to ofloxacin in patients with bone and joint infections
Time frame: day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.